Lower Limb Spasticity

0
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Ipsen
IpsenChina - Tianjin
2 programs
Botulinum toxin type AN/A1 trial
Botulinum toxin type AN/A1 trial
Active Trials
NCT02020980Completed186Est. Mar 2018
NCT03017729Completed242Est. Nov 2020

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
IpsenBotulinum toxin type A
IpsenBotulinum toxin type A

Clinical Trials (2)

Total enrollment: 428 patients across 2 trials

NCT03017729IpsenBotulinum toxin type A

Effectiveness and Safety of Dysport® (abobotulinumtoxinA) in Paediatric Lower Limb Spasticity

Start: Feb 2017Est. completion: Nov 2020242 patients
N/ACompleted
NCT02020980IpsenBotulinum toxin type A

RELIEF Study: Lower Limb Pain Relief After Injection Cycles in Adults Suffering From Lower Limb Spasticity Following Stroke

Start: Apr 2014Est. completion: Mar 2018186 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space